What Value is this? was..... UroToday

[Guest guest]

I just wonder what value a study like this

is. It is a retrospective study and it involves 15 patients.

Can the results really be considered

representative of men on ADT (Androgen Deprivation Therapy)?

And if there is no value then surely

posting it merely clutters up the List?

All the best

Terry Herbert

I have no medical

qualifications but I was diagnosed in ‘96: and have learned a bit since

then.

My sites are at www.yananow.net and www.prostatecancerwatchfulwaiting.co.za

Dr

“Snuffy” Myers : " As a physician, I am painfully aware that most of

the decisions we make with regard to prostate cancer are made with inadequate

data "

From: ProstateCancerSupport [mailto:ProstateCancerSupport ] On Behalf Of Kathy Meade

Sent: Friday, 21 March 2008 12:27

AM

To: Kathy Meade

Subject:

UroToday - Serum Testosterone Recovery After Cessation of Long-Term Luteinizing

Hormone-Releasing Hormone Agonist in Patients with Prostate Cancer - Abstract

Wednesday, 19 March 2008

Department of Urology, Medical University

of South Carolina, ton,

South Carolina, USA.

The time to testosterone recovery after the cessation of androgen

deprivation therapy appears to be dependent on the therapy duration. Most

men will recover normal testosterone levels within 18 months according to

the findings from studies that frequently involved fewer than 3 years of

androgen deprivation therapy. Our goal was to assess the proportion of

patients who remain castrated after cessation of longer duration luteinizing

hormone-releasing hormone (LHRH) agonist therapy for prostate cancer.

We reviewed 15 patients who had received at least 48 months of continuous

goserelin injection therapy for prostate cancer and had not been receiving

the therapy for at least 18 months. The serum testosterone and

prostate-specific antigen data were obtained.

The mean duration of LHRH agonist therapy was 73 months (range 48 to 110).

At the cessation of therapy after a mean follow-up of 31 months, 53% had

testosterone levels that remained castrated. Only 1 patient achieved normal

testosterone levels. Of the patients with greater than castrate testosterone

levels, 71% experienced a prostate-specific antigen rise. All the men with

an intact prostate who had testosterone recovery to greater than castrate

levels had a prostate-specific antigen increase, which might represent a

return toward the pretreatment baseline. Of the patients who started therapy

after age 70 years, 78% remained castrated versus 17% of those who started

before 70 years.

Of the men who had received 4 or more years of LHRH agonist therapy for

prostate cancer, 53% remained castrated up to 2.5 years after therapy

cessation. Patients who started LHRH agonist therapy after age 70 were more

likely to remain castrate after stopping long-term therapy.

Written by

Bong GW, e HS Jr, Hancock WC, Keane TE.

Reference

Urology. 2008 Feb 14. Epub ahead of print.

doi:10.1016/j.urology.2007.09.066

PubMed Abstract

PMID:18279929